All articles tagged with #cerevel therapeutics
AbbVie's experimental schizophrenia drug, emraclidine, acquired through a $9 billion deal with Cerevel Therapeutics, failed to show significant patient improvement in Phase 2 trials. The drug did not outperform a placebo on the Positive and Negative Syndrome Scale (PANSS), leading AbbVie to reassess its next steps.
AbbVie Inc is reportedly close to finalizing an $8 billion deal to acquire Cerevel Therapeutics Holdings Inc, a drug developer specializing in neurological conditions like Parkinson's. This potential acquisition comes shortly after AbbVie's agreement to purchase cancer drug developer ImmunoGen Inc for $10.1 billion, indicating the company's interest in investing in promising new medicines. The deal, which is being negotiated at around $45 per share, could be announced as early as this week.
Pharmaceutical company AbbVie has announced its plans to acquire neuroscience drugmaker Cerevel Therapeutics for approximately $8.7 billion. This acquisition is part of AbbVie's strategy to expand its drug pipeline and address the upcoming generic competition for its top-selling treatments. The deal will strengthen AbbVie's portfolio in the field of psychiatric and neurological disorders, bringing in drugs such as Emraclidine, an experimental treatment for schizophrenia and Alzheimer's disease psychosis. AbbVie expects to complete the acquisition in mid-2024.
AbbVie plans to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion in cash, marking its second major deal in a week after announcing the $10.1 billion acquisition of ImmunoGen. These acquisitions make AbbVie the third-largest biopharma M&A dealmaker of 2023 so far.
AbbVie has announced its acquisition of Cerevel Therapeutics in a deal valued at approximately $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline with Cerevel's robust portfolio of clinical-stage and preclinical candidates targeting psychiatric and neurological disorders. The transaction includes Cerevel's late-stage asset emraclidine, a potential best-in-class antipsychotic for schizophrenia, as well as other assets for Parkinson's disease, mood disorders, and epilepsy. The deal is expected to close in mid-2024, subject to regulatory approvals and shareholder approval.
AbbVie has announced its acquisition of Cerevel Therapeutics, a move that will strengthen AbbVie's neuroscience pipeline with a range of clinical-stage and preclinical candidates for psychiatric and neurological disorders. The transaction, valued at approximately $8.7 billion, will add assets with best-in-class potential, including emraclidine, a potential game-changer in the treatment of schizophrenia. The acquisition is expected to close in mid-2024, subject to regulatory approvals and shareholder approval.